Astera Labs, Inc. $ALAB Stock Holdings Increased by Graham Capital Management L.P.

Key Points

• Graham Capital Management L.P. increased its stake in Astera Labs by 151.8%, owning 50,652 shares valued at over $3 million.
• Equities analysts have given Astera Labs a consensus target price of $135.75, with recent prices set as high as $200.00 by Morgan Stanley.
• Astera Labs reported a 149.5% increase in revenue compared to the same quarter last year, with earnings per share at $0.44, surpassing expectations.

Graham Capital Management L.P. boosted its position in Astera Labs, Inc. (NASDAQ:ALAB - Free Report) by 151.8% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 50,652 shares of the company's stock after acquiring an additional 30,537 shares during the quarter. Graham Capital Management L.P.'s holdings in Astera Labs were worth $3,022,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. NewEdge Advisors LLC acquired a new stake in Astera Labs during the fourth quarter worth about $63,000. Banque Transatlantique SA acquired a new stake in Astera Labs during the fourth quarter worth about $86,000. Gen Wealth Partners Inc acquired a new stake in Astera Labs during the fourth quarter worth about $105,000. Sound Income Strategies LLC increased its stake in Astera Labs by 34.7% during the first quarter. Sound Income Strategies LLC now owns 792 shares of the company's stock worth $47,000 after acquiring an additional 204 shares during the last quarter. Finally, GAMMA Investing LLC increased its stake in Astera Labs by 55.7% during the first quarter. GAMMA Investing LLC now owns 794 shares of the company's stock worth $47,000 after acquiring an additional 284 shares during the last quarter. 60.47% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Astera Labs

In other news, General Counsel Philip Mazzara sold 10,000 shares of Astera Labs stock in a transaction dated Thursday, August 28th. The stock was sold at an average price of $188.70, for a total transaction of $1,887,000.00. Following the sale, the general counsel directly owned 161,573 shares of the company's stock, valued at approximately $30,488,825.10. The trade was a 5.83% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Jack R. Lazar sold 22,500 shares of Astera Labs stock in a transaction dated Wednesday, August 27th. The stock was sold at an average price of $178.42, for a total value of $4,014,450.00. Following the sale, the director directly owned 97,351 shares in the company, valued at approximately $17,369,365.42. The trade was a 18.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 1,649,489 shares of company stock valued at $232,463,986. Company insiders own 12.50% of the company's stock.

Analyst Upgrades and Downgrades

ALAB has been the subject of several research analyst reports. William Blair initiated coverage on Astera Labs in a research note on Thursday, May 22nd. They set an "outperform" rating for the company. Needham & Company LLC upped their price target on Astera Labs from $100.00 to $170.00 and gave the stock a "buy" rating in a research note on Wednesday, August 6th. Barclays restated an "overweight" rating and set a $155.00 price target (up from $75.00) on shares of Astera Labs in a research note on Thursday, August 7th. Northland Securities lowered Astera Labs from an "outperform" rating to a "market perform" rating and set a $120.00 price objective on the stock. in a research report on Tuesday, July 22nd. Finally, Jefferies Financial Group raised their price objective on Astera Labs from $95.00 to $130.00 and gave the company a "buy" rating in a research report on Tuesday, July 22nd. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $142.00.

Astera Labs Trading Up 1.4%

NASDAQ:ALAB traded up $2.37 during mid-day trading on Wednesday, hitting $176.61. The company had a trading volume of 3,124,374 shares, compared to its average volume of 4,925,204. The business has a fifty day simple moving average of $136.10 and a 200-day simple moving average of $96.96. Astera Labs, Inc. has a 1 year low of $36.85 and a 1 year high of $199.47. The firm has a market capitalization of $29.36 billion, a price-to-earnings ratio of 315.38, a PEG ratio of 4.62 and a beta of 1.48.

Astera Labs (NASDAQ:ALAB - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported $0.44 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.33 by $0.11. Astera Labs had a return on equity of 9.53% and a net margin of 16.54%.The business had revenue of $191.93 million for the quarter, compared to analyst estimates of $172.46 million. During the same period in the previous year, the company earned $0.13 earnings per share. The company's revenue for the quarter was up 149.5% compared to the same quarter last year. Astera Labs has set its Q3 2025 guidance at 0.380-0.390 EPS. As a group, research analysts anticipate that Astera Labs, Inc. will post 0.34 earnings per share for the current year.

Astera Labs Profile

Astera Labs, Inc designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform is comprised of a portfolio of data, network, and memory connectivity products, which are built on a unifying software-defined architecture that enables customers to deploy and operate high performance cloud and AI infrastructure at scale.